Overview

Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer

Status:
Not yet recruiting

Trial end date:
0000-00-00

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to test 2 types of dosing schedules of tremelimumab and durvalumab to learn if one is more effective in patients with high-grade, platinum-resistant epithelial ovarian, peritoneal, or fallopian tube cancer. The safety of the dosing schedules will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

M.D. Anderson Cancer Center

Collaborator:

AstraZeneca

Treatments:

Antibodies, Monoclonal
Tremelimumab